Skip to main content
SpringerLink
Log in

The role of oncogenes in drug resistance

  • Chapter
Multiple Drug Resistance in Cancer 2

  • 88 Accesses

Abstract

Increasing evidences indicate that oncogenes can directly or indirectly impact on cancer-cell drug resistance. This chapter provides a conceptual review regarding the role of oncogenes in drug resistance. The review is focused on drug resistance mediated by oncogenes encoding growth factor receptors, signaling molecules, transcription factors, cell-cycle regulators, and apoptosis regulators. It is my hope that better undertsnading on the role of oncogenes in drug resistance will invoke ideas on new approaches to enhance the cytotoxicity of the standard chemotherapeutic agents by functional perturbation of resistance-inducing oncogenes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J and Sela M (1988) Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 80: 1605–1611.

    Article  PubMed  CAS  Google Scholar 

  • Aggarwal BB, Totpal K, Ah-Osman F, Budde RJ and Pocsik E (1994) pp60v-src kinase overexpression leads to cellular resistance to the antiproliferative effects of tumor necrosis factor. FEBS Letters 345: 219–224.

    Google Scholar 

  • Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD and Stewart SJ (1994) p185c-erbB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 54: 3758–3765.

    Google Scholar 

  • Bargmann CI, Hung M-C and Weinberg RA (1986) The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319: 226–230.

    Article  PubMed  CAS  Google Scholar 

  • Bartkova J, Lukas J, Muller H, Strauss M, Gusterson B and Bartek J (1995) Abnormal patterns of D-type cyclin expression and GI regulation in human head and neck cancer. Cancer Research 55: 949–56.

    PubMed  CAS  Google Scholar 

  • Bates S and Peters G (1995) Cyclin D1 as a cellular proto-oncogene. Seminars in Cancer Biology 6: 73–82.

    Article  PubMed  CAS  Google Scholar 

  • Begleiter A, Mowat M, Israels LG and Johnston JB (1996) Chlorambucil in chronic lymphocytic leukemia: mechanism of action. Leukemia and Lymphoma 23: 187–201.

    Article  PubMed  CAS  Google Scholar 

  • Shushan A, Abramson R, Chiu JF and Tritton TR (1992) Expression of c-fos in human and murine multidrug-resistant cells. Mol Pharm t42: 69–74.

    Google Scholar 

  • Carraway KL, Sliwkowski MX, Akita R, Platko JV, Guy PM, Nuijens A, Diamonti J, Vandelen RL, Cantley LC and Cerione RA (1994) The erbB-3 gene product is a receptor for heregulin. J Biol Chem 269: 14303–14306.

    PubMed  CAS  Google Scholar 

  • Chang T, Khalsa O, Wang H, Lee ME and Schlegel R (1996) Staurosporine resistance accompanies DNA tumor virus-induced immortalization and is independent of the expression and activities of ERK1, ERK2, cyclin A, cyclin-dependent kinase (cdk)2, and cdk4. Cell Growth and Duff 7: 361–372.

    CAS  Google Scholar 

  • Chevalier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA and Van Glabbeke M (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase 2 trial of the clinical screening cooperative group of the European Organization for Research and Treatment of Cancer. J of Clin Oncol 13: 314–322.

    Google Scholar 

  • Chrysogelos SA and Dickson RB (1994) EGF receptor expression, regulation, and function in breast cancer. Breast Cancer Res and Treatment 29: 29–40.

    Article  CAS  Google Scholar 

  • Coussens L, Yang-Feng TL, Liao Y-C, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levinson A and Ullrich A (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132–1139.

    Article  PubMed  CAS  Google Scholar 

  • Dickstein B, Valverius EM, Wosikowski K, Saceda M, Pearson JW and Martin MB et al. (1993) Increased epidermal growth factor receptor in an estrogen-responsive, adriamycin-resistant MCF-7 cell line.J Cell Physiol 157.

    Google Scholar 

  • Dixit M, Yang JL, Poirier MC, Price JO, Andrews PA and Arteaga CL (1997) Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal grwoth factor antisense RNA. J Natl Cancer Inst 89: 365–373.

    Article  PubMed  CAS  Google Scholar 

  • Fan Z, Baselga B, Masui H and Mendelsohn J (1993) Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well-established A431 cell xenografts. Cancer Res 53: 4637–4642.

    PubMed  CAS  Google Scholar 

  • Gillett C, Fanti V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D and Peters G (1994) Amplification and overexpression of cyclin Dl in breast cancer detected by immunohistochemical staining. Cancer Res 54.

    Google Scholar 

  • Graus-Porta D, Beerli RR, Daly JM and Hynes NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. The EMBO Journal 16: 1647–1655.

    Article  PubMed  CAS  Google Scholar 

  • Gusterson BA, Gelber RD, Goldhirsch A, Price KN, SaveSoderborgh J, Anbazhagan R, Styles J, Rudenstam C-M, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Burki K, Castiglione M, Collins J, Lindtner J, Senn H-J and Ludwig IBCSG (1992) Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10: 1049–1056.

    PubMed  CAS  Google Scholar 

  • Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP and Shawver LK (1991) A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cisdiamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 51: 4575–4580.

    PubMed  CAS  Google Scholar 

  • Hayes JD and Pulford DJ (1995) The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Critical Reviews in Biochemistry and Molecular Biology 30: 445–600.

    Article  PubMed  CAS  Google Scholar 

  • Hill ME, MacLennan KA, Cunningham DC, Vaughan-Hudson B, Burke M, Clarke P, Di Stefano F, Anderson L, Vaughan-Hudson G, Mason D, Selby P and Linch DC (1996) Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin’s lymphoma: a British National Lymphoma Investigation Study. Blood 88: 1046–1051.

    PubMed  CAS  Google Scholar 

  • Hochhauser D, Schnieders B, Ercikan-Abali E, Gorlick R, MuiseHelmericks R, Li WW, Fan J, Banerjee D and Bertino JR (1996) Effect of cyclin DI overexpression on drug sensitivity in a human fibrosarcoma cell line. Journal of the National Cancer Institute 88: 1269–1275.

    Article  PubMed  CAS  Google Scholar 

  • Hockenbery D, Nunez G, Milliman C, Schreiber RD and Korsmeyer SJ (1990) Bcl-2 is an inner mitochodrial membrane protein that blocks programmed cell death. Nature 348: 334–336.

    Article  PubMed  CAS  Google Scholar 

  • Hockenbery DM, Oltvai ZN, Yin X-M, Milliman C and Korsmeyer SJ (1993) Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75: 241–251.

    Article  PubMed  CAS  Google Scholar 

  • Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK and Hortobagyi GN (1991) Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797–1805.

    Article  PubMed  CAS  Google Scholar 

  • Huang Y, Ibrado AM, Reed JC, Bullock G, Ray S, Tang C and Bhalla K (1997) Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 11: 253–257.

    Article  PubMed  CAS  Google Scholar 

  • Jacquemier J, Penault-Llorca F, Viens P, Houvenaeghel G, Hassoun J, Torrente M, Adelaide J and Birnbaum D (1994) Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression. Anticancer Res 14: 2773–2778.

    PubMed  CAS  Google Scholar 

  • Kitada S, Takayama S, De Riel K, Tanaka S and Reed JC (1994) Reversal of chemoresistance of lymphoma cells by antisensemediated reduction of bcl-2 gene expression. Antisense Research and Development 4: 71–79.

    PubMed  CAS  Google Scholar 

  • Kopnin BP, Stromskaya TP, Kondratov RV, Ossovskaya VS, Pugacheva EN, Rybalkina EY, Khokhlova OA and Chumakov PM (1995) Influence of exogenous ras and p53 on P-glycoprotein function in immortalized rodent fibroblasts. Oncology Research 7: 299–306.

    PubMed  CAS  Google Scholar 

  • Livingstone A and Mairs RJ (1997) N-myc amplification and its relationship to experimental therapy. Journal of Neuro-Oncology 31: 33–39.

    Article  PubMed  CAS  Google Scholar 

  • Marx J (1994) Oncogenes reach a milestone. Science 266: 1942–1944.

    Article  PubMed  CAS  Google Scholar 

  • Masumoto N and Nakano S (1997) Cell signaling and CDDP resistance. Japanese Journal of Cancer and Chemotherapy 24: 424–430.

    PubMed  CAS  Google Scholar 

  • Mendelsohn J and Fan Z (1997) Epidermal Growth Factor Receptor Family and Chemosensitization. J Natl Cancer Inst 89: 341–343.

    Article  PubMed  CAS  Google Scholar 

  • Mizutani Y, Fukumoto M, Bonavida B and Yoshida O (1994) Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. Cancer 74: 2546–2554.

    Article  PubMed  CAS  Google Scholar 

  • Moffat GJ, McLaren AW and Wolf CR (1994) Involvement of Jun and Fos proteins in regulating transcriptional activation of the human pi class glutathione S-transferase gene in multidrugresistant MCF7 breast cancer cells. J Biol Chem 269: 16397–16402.

    PubMed  CAS  Google Scholar 

  • Morabito F, Filangeri M, Callea I, Sculli G, Callea V, Fracchiolla NS, Neri A and Brugiatelli M (1997) Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs. Haematologica 82: 16–20.

    PubMed  CAS  Google Scholar 

  • Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M and Henderson IC (1994) C-erbB-2 expression and response to adjuvant therapy in woman with node-positive early breast cancer. N Engl J Med 330: 1260–1266.

    Article  PubMed  CAS  Google Scholar 

  • Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL and Haber M (1996) Expression of the gene for multidrug-resistanceassociated protein and outcome in patients with neuroblastoma. N Engl J Med 334: 231–238.

    Article  PubMed  CAS  Google Scholar 

  • Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB and Slamon DJ (1994) Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast cancer and ovarian cancer cells. Oncogene 9: 1829–1838.

    PubMed  CAS  Google Scholar 

  • Plowman GD, Grenn JM, Culouscou J-M, Carlton GW, Roth-well VM and Buckley S (1993) Heregulin induces tyrosine phosphorylation of HER4/p180erh8–4 Nature. 366: 473–475.

    CAS  Google Scholar 

  • Ransone LJ and Verma IM (1990) Nuclear proto-oncogenes fos and jun. Annu Rev Cell Biol 6: 539–557.

    Article  PubMed  CAS  Google Scholar 

  • Reed JC (1995) Bcl-2: preventino of apoptosis as a mechanism of drug resistance. Hematology–Oncology Clinics of North America 9: 451–473.

    CAS  Google Scholar 

  • Reeve JG, Xiong J, Morgan J and Bleehen NM (1996) Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. British J of Cancer 73: 1193–1200.

    Article  CAS  Google Scholar 

  • Riva C, el Khyari S, Rustum Y and Barra Y (1995) Resistance to cytosine arabinoside in cells transfected with activated Ha-ras oncogene. Anticancer Research 15: 1297–1302.

    PubMed  CAS  Google Scholar 

  • Riva-Lavieille C (1994) Drug resistance, oncogenes and antioncogenes in epithelial tumors. Bulletin du Cancer 81: 105s - 111s.

    PubMed  Google Scholar 

  • Scanlon KJ, Ishida H and Kashani-Sabet M (1994) Ribozyme-mediated reversal of the multidrug-resistant phenotype. Proceedings of the National Academy of Sciences of the United States of America 91: 11123–11127.

    Article  PubMed  CAS  Google Scholar 

  • Schechter AL, Hung M-C, Vaidyanathan L, Weinberg RA, YangFeng TL, Francke U, Ullrich A and Coussens L (1985) The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 229: 976–978.

    Article  PubMed  CAS  Google Scholar 

  • Sepp-Lorenzino L, Bos M, Ma Z, Baselga J, Rands E and Kohl NE et al. (1996) Farnesyl protein transferase inhibitors (FITs) block tyrosine kinase signal transduction and act in concert with an anti-EGF receptor antibody to inhibit cancer cell growth ( Abstract ). Proc Am Assoc Cancer Res 37: 421.

    Google Scholar 

  • Sklar MD and Prochownik EV (1991) Modulation of cis-platinum resistance in Friend erythroleukemia cells by c-myc. Cancer Research 51: 2118–2123.

    PubMed  CAS  Google Scholar 

  • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182.

    Article  PubMed  CAS  Google Scholar 

  • Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, Fendly BM, Cerione RA, Vandlen RL and Carraway KL (1994) Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 269: 14661–14665.

    PubMed  CAS  Google Scholar 

  • Stoetzer OJ, Nussler V, Darsow M, Gullis E, Pelka-Fleischer R, Scheel U and Wilmanns W (1996) Association of bcl-2, bax, belxL and interleukin-1 beta-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia 10 Suppl 3: S18 - S22.

    Google Scholar 

  • Tang C, Willingham MC, Reed JC, Miyashita T, Ray S, Ponnathpur V, Huang Y, Mahoney ME, Bullock G and Bhalla K (1994) High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 8: 1960–1969.

    PubMed  CAS  Google Scholar 

  • Tanio Y (1992) Relationship between drug resistance and oncogenes in lung cancer cell lines. Nippon Kyobu Shikkan Gakkai Zasshi — Japanese Journal of Thoracic Diseases 30: 42–47.

    Google Scholar 

  • Teixeira C, Reed JC and Pratt MA (1995) Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Research 55: 3902–3907.

    PubMed  CAS  Google Scholar 

  • Tetu B and Brisson J (1994) Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 73: 2359–65.

    Article  PubMed  CAS  Google Scholar 

  • Theodorescu D, Connors KM, Groce A, Hoffman RM and Kerbel RS (1993) Lack of influence of c-Ha-ras expression on the drug sensitivity of human bladder cancer histocultured in three-dimensions. Anticancer Research. 13: 941–946.

    PubMed  CAS  Google Scholar 

  • Tsai C-M, Chang K-T, Perng R-P, Mitsudomi T, Chen M-H, Kadoyama C and Gazdar AF (1993) Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutation. J Natl Cancer Inst 85: 897–901.

    Article  PubMed  CAS  Google Scholar 

  • Tsai C-M, Yu D, Chang K-T, Wu L-H, Perng PR-P, Ibrahim NK and Hung M-C (1995) Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu transfected human lung cancer cells. J Natl Cancer Inst 87: 682–684.

    Article  PubMed  CAS  Google Scholar 

  • Tsai CM, Levitzki A, Wu L-H, Chang KT, Chen C-C, Gazit A and Perng RP (1996) Enhancement of chemosensitivity by tyrphostin AG825 in high-p185ne“ expressing non-small cell lung cancer cells. Cancer Res 56: 1068–1074.

    PubMed  CAS  Google Scholar 

  • Van Waardenburg RC, Prins J, Meijer C, Uges DR, De Vries EG and Mulder NH (1996) Effects of c-myc oncogene modulation on drug resistance in human small cell lung carcinoma cell lines. Anticancer Research 16: 1963–1970.

    PubMed  Google Scholar 

  • Vickers PJ, Dickson RB, Shoemaker R and Cowan KH (1988) A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol Endocrinol 2: 886–892.

    Article  PubMed  CAS  Google Scholar 

  • Walker A, Taylor ST, Hickman JA and Dive C (1997) Germinal center-derived signals act with Bc1–2 to decrease apoptosis and increase clonogenicity of drug-treated human B lymphoma cells. Cancer Research 57: 1939–1945.

    PubMed  CAS  Google Scholar 

  • Wall ME and Wani MC (1995) Camptothecin and Taxol: Discovery to Clinic — Thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 55: 753–760.

    PubMed  CAS  Google Scholar 

  • Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W and Ullrich A (1995) Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO Journal 14: 4267–4275.

    PubMed  CAS  Google Scholar 

  • Wani MC, Taylor HL, Wall ME, Coggon P and McPhail AT (1971) Plant antitumor agents. VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus Brevifolia. J Am Chem Soc 93: 2325–2327.

    Article  PubMed  CAS  Google Scholar 

  • Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe ES and Raffeld M (1997) Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin’s lymphomas. Blood 89: 601–609.

    PubMed  CAS  Google Scholar 

  • Wood DP Jr, Anderson AE, Fair R and Chaganti RS (1992) Ras oncogene point mutations in bladder cancer resistant to cisplatin. Urological Research 20: 313–316.

    Article  PubMed  CAS  Google Scholar 

  • Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T and Toyoshima K (1986) Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor. Nature 319: 230–234.

    Article  PubMed  CAS  Google Scholar 

  • Yamazaki H, Schneider E, Myers CE and Sinha BK (1994) Oncogene overexpression and de novo drug-resistance in human prostate cancer cells. Biochimica et Biophysica Acta 1226: 89–96.

    Article  PubMed  CAS  Google Scholar 

  • Yarden Y and Weinberg RA (1989) Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene. Proc Natl Acad Sci USA 86: 3179–3183.

    Article  PubMed  CAS  Google Scholar 

  • Yu D, Liu B, Sun D, Jing T, Price JE, Singletary SE, Hortobagyi GN and Hung MC (1998) Overexpression of both p1 85c—erbB2 and p170mdr-1renders breast cancer cells highly resistant to Taxol. Oncogene 16: 2087–2094.

    Article  PubMed  CAS  Google Scholar 

  • Yu D, Liu B, Tan M, Li J, Wang S-S and Hung M-C (1996) Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-l-independent mechanisms. Oncogene 13: 1359–1365.

    PubMed  CAS  Google Scholar 

  • Zhang L and Hung M-C (1996) Sensitization of HER-2/neuoverexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tryosine kinase inhibitor emodin. Oncogene 12: 571–576.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Surgical Oncology and Tumor Biology, The University of Texas, M.D. Anderson Cancer Center, Box 107, Houston, TX, 77030, USA

    Dihua Yu

Authors
  1. Dihua Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dihua Yu .

Editor information

Editors and Affiliations

  1. National Cell & Tissue Center, Bioresearch Ireland, Dublin City University, Glasnevin, Dublin, Ireland

    Martin Clynes

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Yu, D. (1998). The role of oncogenes in drug resistance. In: Clynes, M. (eds) Multiple Drug Resistance in Cancer 2. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-2374-9_19

Download citation

  • DOI: https://doi.org/10.1007/978-94-017-2374-9_19

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-90-481-5108-0

  • Online ISBN: 978-94-017-2374-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation